Back

Objective randomised blinded investigation of therapeutic ablation versus cardioversion for persistent atrial fibrillation- outcomes of the feasibility

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: ablation 3 Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Vijayabharathy Kanthasamy

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Pulmonary vein isolation using pulsed field ablation versus high-power-short-duration radiofrequency ablation for paroxysmal atrial fibrillation: efficacy, safety, and long-term follow-up.
Professor N. Reinsch (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Heart rate dynamics after pulmonary vein isolation: pulsed-field vs. radiofrequency ablation
Doctor C. Valeriano (Rozzano, IT)
Abstract Slides Video
Presentation thumbnail
Procedural and outcome impact of body mass index on pulsed field ablation of atrial fibrillation: insights from the EU-PORIA Registry
Doctor A. Telesca (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Impact of age on the management and prognosis of oesophageal fistula after atrial fibrillation ablation - a subanalysis of the worldwide POTTER-AF study
Doctor S. Popescu (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Multielectrode catheter-based pulsed electric field versus cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis
Doctor G. Vetta (Brussels, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: ablation 3
Video

The Event

Event poster

EHRA 2024

7 April - 9 April 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources